EMA Turns Down Nurzigma for Huntington Disease
Medscape,
At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP…
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Overview of attention for article published in Lancet Neurology, December 2018
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (94th percentile)
-
Good Attention Score compared to outputs of the same age and source (69th percentile)
Mentioned by
- news
- 2 news outlets
- blogs
- 1 blog
- 3 X users
- patent
- 4 patents
- 1 Facebook page
- guideline
- 1 clinical guideline source
Readers on
- mendeley
- 231 Mendeley
